BamSEC and AlphaSense Join Forces
Learn More

Amylin Pharmaceuticals Inc

Formerly NASDAQ: AMLN
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1.1
from 8-K 23 pages 13,000,000 Amylin Pharmaceuticals, Inc. Common Stock Underwriting Agreement
12/34/56
EX-1
from DFAN14A 2 pages Eastbourne Calls on All Amylin Shareholders to Vote Today and Support Change to the Amylin Board of Directors Urges Shareholders to Vote on the White Proxy Card and Elect All Three of Eastbourne’s Highly-Qualified Nominees
12/34/56
EX-1
from DFAN14A 5 pages Eastbourne Calls on Amylin Employees to Help Shape the Company’s Future and Support Change to the Board Urges Them to Vote the White Proxy Card and Elect All Three of Its Nominees Who Are Committed to Acting in Shareholders’ Best Interests
12/34/56
EX-1
from DFAN14A 5 pages Eastbourne Sends Letter to Amylin Board Eastbourne Cites Broad Recommendation for Change by Independent Proxy Voting Advisory Services Eastbourne Urges Shareholders to Vote the White Proxy Card and Elect Its Highly-Qualified and Independent Director Nominees
12/34/56
EX-1
from DFAN14A 2 pages Fourth Independent Proxy Advisory Firm Recommends Change to Board of Directors at Amylin Pharmaceuticals Egan Jones Is the Latest to Support Eastbourne and Icahn Nominees Eastbourne Urges Shareholders to Vote the White Proxy Card and Elect All Three of Its Nominees Who Are Committed to Acting in Shareholders’ Best Interests
12/34/56
EX-1
from DFAN14A 4 pages Riskmetrics Supports Change to the Board of Directors at Amylin Supports Election of Two Eastbourne Nominees and One Icahn Nominee Eastbourne Urges Shareholders to Elect All Three of Its Nominees Who Are Committed to Acting in Shareholders’ Best Interests
12/34/56
EX-1
from DFAN14A 5 pages Eastbourne Capital Sends Letter to Amylin Shareholders Outlining Broad Call for Change to Amylin Board Notes That Company Is Spending Millions to Maintain Status Quo Urges Shareholders to Vote the White Proxy Card and Elect Eastbourne’s High-Qualified and Independent Director Nominees
12/34/56
EX-1
from DFAN14A 4 pages Three Leading Independent Proxy Advisory Firms Now Support Change at Amylin Pharmaceuticals Glass Lewis and Proxy Governance Join Riskmetrics Group in Recommending That Amylin Shareholders Support Eastbourne and Icahn Nominees “Most of the Amylin Shareholders to Whom We Spoke, Even the Shareholders That Are Likely to Support the Company, Acknowledge That Amylin Has Not Fired on All Strategic Pistons.”
12/34/56
EX-1
from DFAN14A 4 pages Amylin’s Statements Are Unsubstantiated and Conclusory Says Eastbourne Incumbents’ Record as Managers Is Real Issue Facing Shareholders Shareholders Representing Nearly a Quarter of the Company Are Supporting Change to Give Amylin a Real Chance for Commercial Success
12/34/56
EX-1
from DFAN14A 3 pages Eastbourne Capital Files Presentation Outlining the Case for Change at Amylin Pharmaceuticals
12/34/56
EX-1
from DFAN14A 2 pages Eastbourne Capital Comments on Recent Developments Regarding Amylin Pharmaceuticals
12/34/56
EX-1
from DFAN14A 4 pages Eastbourne Capital Sends Letter to Amylin Pharmaceuticals Board of Directors Files Preliminary Proxy Materials
12/34/56
EX-1
from DFAN14A 2 pages Eastbourne Capital Comments on Amylin Pharmaceuticals Lawsuit in Delaware and Recent Developments in Effort to Enjoin Company’s “Poison Puts” Criticizes Company’s Announced Slate Calling Effort “Too Little Change, Too Late”
12/34/56
EX-1
from DFAN14A 2 pages Eastbourne Capital Management Comments on Delaware Lawsuit to Enjoin Amylin Pharmaceuticals “Poison Puts” Applauds San Antonio Fire and Police Pension Fund Action
12/34/56
EX-1
from DFAN14A 4 pages Eastbourne Capital Management Sends Letter to Amylin Pharmaceuticals Board of Directors Calls on Board to Immediately Address Corporate Governance Issues and Remove Impediments to a Free and Open Election Process
12/34/56
EX-1
from DFAN14A 2 pages Certain Information Concerning Participants
12/34/56
EX-1.1
from 8-K 33 pages Amylin Pharmaceuticals, Inc. 3.00% Convertible Senior Notes Due 2014 Purchase Agreement
12/34/56
EX-1.1
from 8-K 24 pages Amylin Pharmaceuticals, Inc. Common Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 28 pages Amylin Pharmaceuticals, Inc. Common Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 27 pages Amylin Pharmaceuticals, Inc. Common Stock Underwriting Agreement
12/34/56